RIVastigmine In Vascular cognitivE Impairment "RIVIVE"

Completed

Phase 4 Results N/A

Summary of Purpose

The study is a 24-week prospective, double blind, randomized, placebo-controlled pilot study of 9 mg / day Rivastigmine in patients with Vascular Cognitive Impairment Not Dementia (CIND) to evaluate efficacy, safety and tolerability in Asian patients. The hypothesis is that patients receiving Rivastigmine would improve in executive functioning domains.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 29 April 2008.

1 Feb 2006 28 Apr 2008 1 Apr 2007 1 Feb 2008 1 Apr 2008 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available